3 results
Primary objectives:The primary objectives of this trial are:• To show PK similarity of BI 695500 to MabThera® and Rituxan® and of Rituxan® to MabThera® (three-way PK similarity).• To establish statistical equivalence of efficacy of BI 695500 and…
This study aims to gain insight in the in the level of fibrinolysis in patients with traumatic brain injury in the first 24 hours following trauma.Primairy objective:- To determine the 24-hour prevalence and course of fibrinolysis in patients with…
Our research group recently found that almost 50% of all OHCA patients develop hyperfibrinolysis, and found an interesting association between the degree of hyperfibrinolysis and hypoperfusion. Hypoperfusion was determined by base excess (BE),…